Loading…
Qingdao oncology-focused healthcare group, controlled by Haier, running cancer hospitals and making gamma-knife radiotherapy equipment.
Qingdao oncology-focused healthcare group, controlled by Haier, running cancer hospitals and making gamma-knife radiotherapy equipment.
Earns most of its income from running hospitals, mainly cancer-focused ones in Sichuan and Suzhou, paid by patients and insurers, with a smaller line selling Masep gamma knives and radiotherapy machines to other hospitals. Haier Group took control in 2019 and built the hospital business on top of the gamma-knife maker it inherited.
Moat: narrow (regulatory licence, installed base). Licensed hospital network and a gamma-knife installed base; both are fragmented, local markets.
Headquarters: Qingdao, China · Founded: 1998 · Employees: 2,662
Size INKON Life Technology (300143.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.08B, the 2158th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥7.45 on 6 Nov 2026.
Performance Over six months the shares fell 13.9%, against -3.6% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 22.0% over the last twelve months (peer median +11.0%); the operating margin is 11.8% (peer median 7.2%).
Valuation It trades at 55.2× forward earnings against a peer median of 20.9× (4th most expensive of 12).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.8 points above its cost of capital (8.5% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.06B | CN¥1.88B | CN¥1.56B | CN¥1.47B | CN¥1.16B |
| Revenue growth | — | +21% | +6% | +27% | — |
| Gross profit | CN¥647M | CN¥476M | CN¥372M | CN¥389M | CN¥294M |
| EBITDA | n/a | CN¥321M | CN¥216M | CN¥225M | CN¥169M |
| Net income | CN¥83.7M | CN¥68.5M | CN¥115M | CN¥100M | -CN¥596M |
| Free cash flow | CN¥339M | CN¥114M | CN¥60.6M | CN¥31.8M | CN¥35.3M |
| Capital expenditure | CN¥156M | CN¥227M | CN¥199M | CN¥158M | CN¥125M |
| Total debt | CN¥805M | CN¥763M | CN¥336M | CN¥299M | CN¥115M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| INKON Life Technology 300143.SZ | $1.08B | -14% | +22% | 12% | 55.2× | 12.4% |
| Hygeia Healthcare 6078.HK | $861M | -7% | +2% | 14% | 11.0× | 4.8% |
| Elekta EKTA-B.ST | $2.37B | +8% | -7% | 6% | 15.1× | 10.0% |
| Siemens Healthineers SHL.DE | $55.9B | +31% | -1% | 15% | 18.9× | 9.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300143.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.6% | +1.2% | 8th lowest of 21 |
| 6-month return | -13.9% | -3.6% | 10th lowest of 20 |
| Distance from 52-week high | -32.6% | -38.2% | 10th highest of 21 |
| Revenue growth (TTM) | +22.0% | +11.0% | 4th highest of 20 |
| Operating margin | 11.8% | 7.2% | 7th highest of 20 |
| Forward P/E | 55.2× | 20.9× | 4th most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | 12.4% | 7.7% | 4th most demanding of 10 |
| Growth delivered (Del g) | +12.9% | +8.8% | 2nd highest of 10 |
| Hurdle (Req g minus delivered) | -0.5 pp | +1.3 pp | 5th least demanding of 10 |
| ROIC minus cost of capital | +2.8 pp | -5.8 pp | 6th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| INKON Life Technology 300143.SZ | China | $1.08B | -14% | +22% | 12% | 55.2× | 12.4% | +12.9% |
| Tinavi Medical Technologies 688277.SS | China | $1.08B | -30% | -2% | -59% | n/a | n/a | n/a |
| PHC 6523.T | Japan | $1.09B | +36% | +3% | 7% | 7.9× | -2.3% | +3.6% |
| L&C BIO 290650.KS | South Korea | $1.07B | -17% | +53% | 17% | 213.2× | n/a | n/a |
| SI-BONE SIBN | United States | $1.09B | +98% | +14% | -8% | n/a | n/a | n/a |
| Freenome FRNM | United States | $1.09B | n/a | n/a | n/a | n/a | n/a | n/a |
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 34% | 20.9× | 6.5% | +10.3% |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 36.0× | 19.1% | +21.5% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | n/a | n/a | n/a |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 18.8× | 7.7% | -2.9% |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 5.8× | 5.2% | +3.6% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 18.2× | 1.5% | +9.9% |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | n/a | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 33.7× | 10.0% | +8.8% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 15.0× | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | n/a | 53.9% | +8.6% |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | n/a | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | n/a | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | n/a | n/a | n/a |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 3,912.9× | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 188.9× | 40.1% | +12.4% |